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Epstein–Barr virus (EBV) in breast milk and subclinical mastitis (SCM) are both associated with human immunodeficiency virus (HIV)
shedding and possibly with postnatal HIV transmission. The objective of this nested case–control study was to investigate the
interplay between SCM and EBV replication in breast milk of HIV-infected mothers.
The relationships between EBV deoxyribonucleic acid (DNA) shedding, HIV-1 ribonucleic acid (RNA) level, and SCMwere explored
in breast milk samples of Zambian mothers participating in the ANRS 12174 trial. Mammary gland inflammation was defined as a
breast milk sodium to potassium ratio (Na+/K+) greater than 0.6 and further subclassified as either “possible SCM” (Na+/K+ ratio
0.6–1.0) or SCM (Na+/K+ ratio≥1.0). Breast milk interleukin 8 (IL-8) was measured as a surrogate marker of mammary gland
inflammation.
EBV DNA was detected in breast milk samples from 42 out of 83 (51%) participants and was associated with HIV-1 shedding in
breast milk (P=0.006). EBV DNA levels were higher in samples with SCM and “possible SCM” compared to non-SCM breast milk
samples (P=0.06; P=0.007). An EBV DNA level of >200copies/mL was independently associated with SCM and “possible SCM”
(OR: 2.62; 95%: 1.13–6.10). In patients with SCM, higher EBV replication in the mammary gland was associated with a lower
induction of IL-8 (P=0.013). Resistance to DNase treatment suggests that EBV DNA in lactoserum is encapsidated.
SCM and decreased IL-8 responses are associated with an increased EBV shedding in breast milk which may in turn facilitate HIV
replication in the mammary gland.
Abbreviations: ART=antiretroviral therapy, AUC=area under the curve, CI=confidence interval, CMV=cytomegalovirus,
DNA=deoxyribonucleic acid, DNase=deoxyribonuclease, EBV=Epstein–Barr virus, GE=genome equivalent, GEE=Generalized
Estimating Equation, HIV=human immunodeficiency virus, IL-8= interleukin 8, IQR= interquartile range, MTCT=mother-to-child
transmission, RANTES=Regulated on Activation, Normal T cell Expressed and Secreted, RNA= ribonucleic acid, ROC= receiver
operating characteristic, SCM=subclinical mastitis, WHO=World Health Organization.
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Breastfeeding is one of the main guaranties of an infant’s health
and normal development.[1,2] While encompassing most essential
nutrients, vitamins and immunologically active components,
breast milk still remains a source of human immunodeficiency
virus (HIV) mother-to-child transmission (MTCT) especially in
resource-limited countries.[3] Studies in Africa have shown that
antiretroviral therapy (ART) significantly reduces HIV MTCT
through breast milk.[4,5] Currently ART is recommended for all
HIV-positive lactating mothers regardless of CD4 T cell counts
and clinical stage of the disease.[6]
Mastitis, an inflammation of the breast tissue is a well-
established risk factor for postnatal HIV MTCT.[7,8] One
suggested explanation is that inflammation increases the
permeability of mammary gland epithelia by which leukocytes
and plasma, with cell-associated and cell-free HIV, respectively,
leak into the breast milk. Inflammation also affects local
electrolyte balance in breast milk resulting in elevated sodium
(Na+) relative to potassium (K+) concentration. Increased breast
milk Na+ concentration or Na+/K+ ratio are used to detect the
clinically silent form of mastitis, termed subclinical mastitis
(SCM). Assessment of interleukin 8 (IL-8) levels, leukocyte
+ +
Sanosyan et al. Medicine (2016) 95:27 Medicinecounts, and enzymes in breast milk have also been used to
evaluate and diagnose SCM.[9–12] SCM is quite common;
Nussenblatt et al[12] have reported a 27% prevalence of SCM
in HIV infected Malawian breastfeeding mothers. Mixed
breastfeeding (combination of breast milk and other foods)
may result in more frequent SCM.[10]
Virus coinfections such as cytomegalovirus (CMV) and/or
Epstein–Barr virus (EBV) also contribute to HIV shedding in
breast milk. CMV deoxyribonucleic acid (DNA) is persistently
found in breast milk and high CMV DNA levels are generally
observed in HIV-infected mothers.[13] Furthermore, we recently
reported that high breast milk CMV DNA levels are associated
with HIV MTCT independently of HIV ribonucleic acid (RNA)
levels.[14] Breast milk EBV DNA has also been shown to be
associated with RNA shedding of HIV-1 in breast milk,[15] and
EBV shedding is more frequently detected in the breast milk of
mothers transmitting HIV postnatally as compared to non-
transmitters.[14]
EBV is a gamma herpesvirus infecting epithelial cells and
memory B cells.[16] More than 90% of the adult human
population are EBV carriers. Primary infection occurring via
virus present in the saliva is usually asymptomatic in children and
causes infectious mononucleosis in adolescents and adults.
Although viral persistence is generally asymptomatic, EBV
infection is involved in development of B cell lymphomas. EBV
establishes a lifelong latent cycle in memory B cells, periodically
entering in lytic replication and virus shedding in oropharyngeal
mucosa.[16,17] HIV infection and malaria exposure are involved
in dysregulation of EBV persistence.[18] B cell activation and
terminal differentiation into plasma cell is a requisite to initiate
EBV lytic replication from latently infected cells.[19]
Here, we investigated the interplay between SCM and EBV
shedding in the mature breast milk of HIV-infected mothers. We
also examined the relationships between EBVDNA shedding and
IL-8 levels, EBV DNA and HIV-1 RNA shedding, and the
presence of encapsidated EBV in breast milk.2. Materials and methods
2.1. Study population and samples
The source population for this nested study was the cohort of
1273 HIV-infected mothers who participated in a multicenter
randomized controlled trial (PROMISE-PEP/ANRS 12174,
NCT00640263) conducted in Burkina Faso, South Africa,
Uganda, and Zambia.[20,21] Women included were not eligible
for ART based on World Health Organization (WHO)
recommendations at the time (enrollment between 2009 and
2012).
Mothers were advised to exclusively breastfeed their infants
during the first 6 months postpartum and were thereafter advised
to introduce complementary foods and stop breastfeeding by
week 49.
The main trial protocol and results have been described
elsewhere.[21] Substudies from this trial including the one
presented herein have been approved by the scientific PROM-
ISE-PEP committee in April 2014.
After providing an informed consent, mature breast milk
samples from HIV-infected Zambian mothers were collected at
38th week postpartum, the first available point after the end of
exclusive breastfeeding. Mothers with at least unilateral SCM or
“possible SCM” were randomly selected as cases (n=33) and
mothers without SCM were selected as controls (n=50) for this2
nested study. Breast milk was expressed manually in sterile 50mL
conical tubes. The specimens were stored at80°C before testing.
Lactoserum was separated from the cellular pellet after 5minutes
centrifugation at 5000rpm.2.2. Na /K ratio measurement
Presence of SCM was evaluated by the Na+/K+ ratio. SCM was
defined as a Na+/K+ ratio≥1.0, “possible SCM” by a Na+/K+
ratio ranging from 0.6 to 1.0, and non-SCM samples a Na+/K+
ratio<0.6.[22,23]
Stored lactoserum was diluted 101-fold in deionized water
prior to testing. Na+ and K+ concentrations in the aqueous
fraction were assessed using a PFP7 flame photometer (Jenway,
Staffordshire, United Kingdom) as previously described.[23]2.3. Assessment of breast milk IL-8
Stored aliquots of lactoserum were used. IL-8 levels were
measured by an enzyme-linked immunosorbent assay (Human
Standard ELISA Development Kit, PeproTech, Inc., CT),
according to the manufacturer’s instructions, and read out using
a microplate reader (Multiskan FC, Thermo Scientific, Vantaa,
Finland).2.4. Monitoring CD4 T cell counts and HIV-1 RNA loads in
plasma and breast milk
CD4 T-lymphocyte counts were measured by flow cytometry
using a fluorochrome-conjugated mAb (FACSCalibur, BD, San
Jose, CA). Breast milk HIV RNA was extracted from 1.0mL of
sample using QIAamp UltraSens Virus Kit (Qiagen, Hilden,
Germany). Plasma HIV RNA was extracted by QIAamp
mini viral RNA mini kit using 200mL of sample. HIV-1 RNA
was quantitated using a commercial real-time RNA PCR
test (Generic HIV Charge Virale, Biocentric, Bandol, France)
with a low detection limit of 300 HIV RNA copies/mL in
plasma[24] and 50 HIV RNA copies/mL for lactoserum. Breast
milk HIV-1 RNA levels below the threshold, but not 0, were
arbitrarily assigned a value equal to half of the threshold
(25copies/mL).2.5. Quantification of EBV DNA and human cell-free DNA
DNA was extracted from 200mL of lactoserum using an
automated QIAamp DNA Mini QIAcube Kit according to the
manufacturer’s protocol (Qiagen). EBV DNA was amplified
using primers within the BamHI-W region of the EBV genome
and described elsewhere.[25] A calibration curve was plotted
using serial dilutions of first WHO international EBV standards
(National Institute for Biological Standards and Control (NIBSC)
reference number 09/260). A threshold set at 200 EBV DNA
copies/mL of breast milk was used to define moderate/high viral
load in breast milk, based on results of previous studies.[14,26]
Human cell-free DNA was quantified in lactosera to control
the DNA extraction, control the deoxyribonuclease (DNase) I
assay efficacy, and quantify lysed cells in acellular part of breast
milk. For this purpose b globin was used as a target gene as
described.[27] A calibration curve was plotted using serial
dilutions of human genomic DNA (Biocentric), with a reference
value of 6.6pg of DNA per human diploid cell.[28] Results of b
globin PCR were expressed as human cell genome equivalents
(GEs) per mL.
Table 1
Clinical characteristics of study participants and samples.
Characteristics Value
Age (mean, SD) 26.8 (5.3)
Primiparous (N, %) 13 (16.2%)
Multiparous (N, %) 70 (83.8%)
Breast milk samples (N) 163
SCM
Mothers without SCM (N, %) 50 (60.2%)
Mothers with SCM and “possible SCM” (N, %) 33 (39.8%)
Breast milk samples
Non-SCM (Na+/K+<0.6) (N, %) 113 (69.3%)
“Possible SCM” (Na+/K+: 0.6–1.0) (N, %) 19 (11.7%)
SCM (Na+/K+≥1.0) (N, %) 31 (19.0 %)
HIV
Plasma HIV-1 RNA log10 copies/mL (mean, SD) 5.07 (5.33)
Sanosyan et al. Medicine (2016) 95:27 www.md-journal.com2.6. DNase I assay for assessment of encapsidated
Epstein–Barr virus
EBV positive breast milk samples were treated with the DNase I
enzyme (DNase recombinant I, RNase free, Roche, Mannheim,
Germany). Briefly, 100mL of lactoserumwas exposed to 100U of
DNase I, 20mL of 10 incubation buffer and RNase-free water
in a total volume of 200mL and incubated at 37°C for 2hours. A
DNase I concentration of 100U was chosen as it destroys more
than 90% of the human cell-free DNA (b globin) in lactosera.
DNase I was then inactivated at 75°C for 10minutes. EBV viral
loads were determined by qPCR as described above, comparing
loads pre- and postexposure to DNase I; the presence of
encapsidated DNA was defined as a decrease in EBV DNA of
<1.0 log10 following DNase I treatment.CD4 T cells/mL (mean, SD) 634 (187)
Breast milk HIV-1 RNA shedding (N, %) 74/161 (46.0%)
Breast milk HIV-1 RNA log10 copies/mL (mean, SD) 3.69 (4.71)
HIV=human immunodeficiency virus, N=number, RNA= ribonucleic acid, SCM= subclinical
mastitis, SD= standard deviation.2.7. Statistical analysis
The Mann–Whitney test for nonparametric data was used to
compare viral loads in different groups and the Spearman
correlation coefficient was used to describe the correlations
between left and right breast milk EBV DNA loads. Wilcoxon
matched-pairs signed rank test was used to compare EBV DNA
loads between 2 breast milk samples from mothers with
unilateral mastitis. Frequencies of viral shedding in different
groups were compared using 2-tailed Fisher exact test. Odds ratio
(OR) was calculated for quantifying the association between
HIV-1 RNA and EBV DNA in lactoserum, and the relation
between moderate/high EBV DNA and SCM. Generalized
Estimating Equation (GEE) variant of logistic regression analysis
was used to evaluate the potential impact of SCM and “possible
SCM” onmoderate/high EBV loads in breast milk. The described
model was chosen as it computed the regression coefficients
assuming potential nonindependence between left and right
breast milk samples. Maternal age, parity, breast milk HIV-1
RNA, and blood CD4 T cell counts were included in the analysis
to evaluate the independency of associations. Factors having P
values more than 0.2 in crude estimates were not further
evaluated in adjusted estimates. Receiver operating characteristic
(ROC) curves were plotted to assess the diagnostic potential of
human cell-free DNA (b globin) and IL-8 as markers of SCM.
Except the GEE model, where both breast milk variables were
combined per mother, in all other analyses breast milk data are
analyzed separately. All viral loads were log transformed and
undetectable viral loads were transformed to logarithmic zeros
for analyses. Statistical analyses and graphs were performed by
GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA)
and IBM SPSS statistics 20 software (SPSS, Inc., Chicago, IL).Table 2
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b globin DNA, GE/mL
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2.9 (0.0–3.6) 1.1 (0.0–2.0) <0.0001
GE=genomic equivalents, HIV=human immunodeficiency virus, IQR= interquartile range, RNA=
ribonucleic acid, SCM= subclinical mastitis.
∗
Median (IQR).3. Results
3.1. Clinical characteristics of participants and SCM
This study included 163 breast milk samples from 83 HIV-
infected mothers (80 bilateral samples and 3 unilateral).
Sociodemographic, obstetrical, and clinical characteristics are
presented in Table 1. SCM and “possible SCM” were detected in
40% of the mothers. Notably, breast milk from specimens with
SCM contained significantly higher levels of IL-8, human cell-free
DNA, and HIV-1 RNA as compared to non-SCM samples
(Table 2, P<0.0001).
Human cell-free DNA in lactosera, reflecting lysed breast milk
cells, was assessed as a surrogate marker for SCM detection.
ROC plots demonstrated an area under the curve (AUC) of 0.963
(95% confidence interval [CI], 0.93–0.99) for cell-free DNA and
0.90 (95% CI, 0.82–0.97) for IL-8, as a means of identifying
patients with SCM. The use of human cell-free DNA as a marker
of SCM showed a sensitivity and specificity of 90.3 % and
90.2%, respectively, at a threshold level of 7,220GE/mL
(Supplementary Fig. 1, http://links.lww.com/MD/B99).3.2. Link between SCM and EBV DNA shedding in breast
milk
Breast milk EBV DNA was detected in 51% of mothers (42/83),
and 39% of breast milk samples (64/163). EBV DNA levels
ranged from 0 to 88,300copies/mL. Twenty-two mothers (27%)
tested positive for EBV DNA bilaterally. EBV DNA loads were
correlated between left and right breast milk samples (Rho=
0.65; P<0.0001) (Fig. 1A). HIV-1 RNA shedding was more
frequent in EBV-positive breast milk samples as compared with
EBV-negative samples (59.3% vs 37.1%, P=0.006) with OR:
2.48 (95% CI, 1.3–4.73; Fig. 1B). HIV-1 RNA loads were also
higher in EBV-positive as compared to EBV-negative breast milk
samples (median: 79.6copies/mL; IQR: 7.0–338.6 vs 25.0copies/
mL; IQR: 0–208.1; P=0.008).
EBV DNA was detected in 51.0% of samples with SCM
(16/31), and 34.5% of non-SCM samples (39/113; P=0.097).
Furthermore, moderate/high breast milk EBV viral loads (>200
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Figure 1. EBV and HIV shedding in breast milk. (A) Most women (n=83) have similar levels of EBV DNA being secreted from both breasts. (B) More HIV RNA can be
detected in milk when EBV DNA is also present in the milk.
Sanosyan et al. Medicine (2016) 95:27 Medicine(10/31; 32.2%) than in non-SCM samples (16/113; 14.1%; P=
0.033). The median values and interquartile ranges (IQRs) of
EBV DNA levels in EBV-positive samples were: 2.48 (1.92–3.30)
log10copies/mL in SCM samples; 2.51 (2.35–4.58) log10copies/
mL in “possible SCM” samples and 2.04 (1.48–2.78) log10
copies/mL in non-SCM samples, respectively (Fig. 2A).
To evaluate the association between SCM and EBV levels
within an individual breastfeeding mother, EBV DNA levels were
compared in paired samples collected from mothers with
unilateral SCM. In 9 of 10 mothers, EBV shedding was higher
in milk samples from the breast with SCM (median: 2.35 log10
copies/mL; IQR: 1.96–3.14) as compared with the contralateral
side (median: 0.43 log10copies/mL; IQR: 0.0–2.26; P=0.006;
Fig. 2B).
Within samples with SCM, EBV shedding was also associated
with the presence of human cell-free DNA. The frequencies of
EBV-positive samples within samples with human cell-free DNA
≥7220GE/mL were 50% (23/46), whereas only 33% (39/117)
were positive in those samples with a level of human cell-free
DNA <7220GE/mL (P=0.07). Furthermore, the levels of EBV
DNA within the former group were significantly higher (median:
2.54 log10copies/mL; IQR: 2.02–4.10) than in the latter group
(median: 2.12 log10copies/mL; IQR: 1.50–2.81; P=0.01;
Supplementary Figure 2A, http://links.lww.com/MD/B99).
Based on the same human cell-free DNA threshold (7220GE/
mL), 15 mothers with unilateral mastitis showed evidence of EBV
shedding. Within this group, 12 of 15 mothers presented with a
higher EBV DNA load (median: 2.36 log10copies/mL; IQR:
1.91–3.07) in the breast milk samples with higher human cell-free
DNA as compared with contralateral breast milk samples
(median: 1.03 log10copies/mL; IQR: 0.0–2.42; P=0.012;
Supplementary Figure 2B, http://links.lww.com/MD/B99).
3.3. Association of IL-8 levels with EBV shedding in SCM
breast milk samples
Interestingly, when assessed all together, IL-8 concentrations did
not differ between EBV-positive and EBV-negative breast milk
specimens. Nevertheless, when IL-8 levels were evaluated in SCM
and “possible SCM” samples, they were significantly lower in the
EBV-positive as compared to the EBV-negative samples (median
(IQR): 263pg/mL (107–1059) vs 793pg/mL (421–2273) in SCM
samples (P=0.013) and 36.1pg/mL (29.6–81.0) vs 181.5
(85.9–215.3) in “possible SCM” samples (P=0.02); Fig. 2C4
and D). In marked contrast, IL-8 levels were not significantly
different in EBV-positive and EBV-negative non-SCM samples
(84.0pg/mL (29.3–134.8) vs 65.2pg/mL (36.2–97.9); P=0.35;
Fig. 2E).3.4. EBV in breast milk: free or encapsidated DNA?
DNase exposure prior to DNA extraction was used to assess
whether EBV DNA was encapsidated and therefore protected
from enzymatic digestion. Beta globin DNA quantification was
used as a human cell-free DNA control. DNase I treatment
resulted in a dramatic decrease in b globin DNA with a median
(IQR) change from 14,500GE/mL (10,850–25,075) before
DNase treatment to 0.0GE/mL (0.0–971.3) after DNase
treatment. Among 12 EBV positive breast milk samples 4
(33%) showed a lack or negligible decrease of EBV DNA after
DNase exposure with median (IQR) change from 2.78 log10
copies/mL (2.68–2.98) before DNase exposure to 2.48 log10
copies/mL (2.44–2.54) after DNase exposure suggesting that
EBV DNA was protected from DNase of samples (data not
shown). The remaining 8 samples became undetectable (from
2.63 to 0.0 log10copies/mL) (data not shown).3.5. Multivariate analysis
Multivariate analysis was used to evaluate the potential impact of
SCM and “possible SCM” on EBV replication in breast milk
(Table 3). We found that SCM as well as “possible SCM” were
independently associated with EBV replication at levels >200
copies/mL in breast milk (OR: 2.62; 95% CI: 1.13–6.10).4. Discussion
Our results evidence the association between SCM and EBV
replication in mature breast milk of HIV-1 positive mothers, with
local immunological factors such as IL-8 interacting with EBV
replication in the mammary gland.
EBV was detected in lactoserum of 51% of the mothers tested
in this study. Notably, the frequency of HIV-1 RNA shedding
and viral load was significantly higher in EBV-positive as
compared to EBV-negative breast milk samples. These data are in
agreement with a similar report showing that the association
between breast milk EBV DNA and HIV-1 RNA is independent
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Figure 2. Relationship between EBV DNA level in breast milk and SCM. (A) Within EBV positive breast milk samples those with SCM and “possible SCM” have
higher EBV load compared to non-SCM samples. (B) In mothers with unilateral SCM higher breast milk EBV DNA levels are detected in the site of SCM. Each pair
represents samples collected at the same time from the 2 mammary glands of 1 mother. (C–E) IL-8 concentration according to breast milk EBV DNA shedding. In
SCM (C) and “possible SCM” samples (D) IL-8 concentrations are significantly higher in EBV DNA negative breast milk samples compared to EBV DNA positive
samples, whereas in non-SCM samples (E) IL-8 concentrations are not different. SCM=subclinical mastitis.
Sanosyan et al. Medicine (2016) 95:27 www.md-journal.comEBVDNA levels were higher in SCMas compared to non-SCM
breast milk samples. Furthermore, assessment of breast milk
samples from the 2 mammary glands of mothers with unilateral
SCM confirmed the link between SCM and EBV DNA shedding
independently of host systemic factors. Specifically, EBV DNA
levels were significantly higher in breast milk from the mammary
gland with SCM than from the contralateral side. However, EBV
detection was not more frequent in SCM samples, suggesting that
low levels of EBVDNA are a frequent finding in the breast milk of
HIV-infected mothers, as previously observed.[15] Multivariate
analyses showed that a level of EBV DNA of >200copies/mL is
associated with SCM and “possible SCM.”
SCM in humans is a recently proposed entity, characterized by
increased mammary gland permeability and leakage of plasma
components and leucocytes into breast milk.[23] The prevalence
of SCM in lactating mothers has been reported to range between
10% and 45%[29,30] and this prevalence does not appear to be
altered in HIV-infected mothers.[31] SCM is generally defined by
high Na+ concentration or Na+/K+ ratio in breast milk.[32,33]
Breast milk cell count and secretory leukocyte protease inhibitor
activity can also be used to detect SCM.[8,12] As cellular DNA is5
released during apoptosis and necrosis we measured human
cell-free DNA in breast milk to explore lysed cells. Our data show
that the quantification of human cell-free DNA in breast milk
may serve as a surrogate marker for SCM. Moreover, SCM has
also been associated with increased production of proinflamma-
tory mediators such as IL-8, RANTES, and lactoferrin[9,10,35,36]
and in our study as well, high IL-8 levels strongly correlated with
this condition.
EBV is frequently detected in the breast milk of women with
chronic EBV infection,[36] irrespective of HIV infection. Junker
et al[37] reported an overall 46% prevalence of EBV DNA in the
cellular fraction of breast milk in the general population. Further
studies also demonstrated frequent EBV DNA in the acellular
breast milk fraction, called lactoserum or whey.[26] EBV shedding
in breast milk is higher during the first weeks of breastfeeding and
decreases in mature breast milk.[26,37] Notably though, EBV is
rarely detected in the plasma of healthy people[38] and even in
HIV-infected individuals, EBV DNA is confined to the cellular
fraction of the blood.[39,40]
The replication of EBV depends on the activation and
maturational stage of the infected B cell.[19,41] An EBV-specific
Table 3
Generalized Estimating Equation version of logistic regression model.
Crude estimates Adjusted estimates
OR 95% CI P OR 95% CI P
Parity
1–2 —
≥3 1.97 (0.76–5.13) 0.165 1.81 (0.69–4.76) 0.232
SCM (Na+/K+)
Non-SCM —
SCM and “possible SCM”
∗
3.1 (1.50–6.40) 0.002 2.62 (1.13–6.10) 0.025
Breast milk HIV-1 RNA, copies/mL
<50 —
≥50 2.02 (0.80–5.06) 0.135 1.41 (0.50–4.0) 0.521
CD4+ T cells, cells/mL
<500 —




≥30 2.07 (0.68–6.23) 0.216
Adjusted estimates demonstrate an independent association between SCM and “possible SCM” and breast milk Epstein–Barr virus (EBV) deoxyribonucleic acid (DNA) shedding at the level more than 200copies/
mL.
OR= odds ratio, SCM= subclinical mastitis.
∗
Na+/K+≥0.6.
Sanosyan et al. Medicine (2016) 95:27 Medicinecellular response is pivotal in the protective immunity against
EBV reactivation.[42] EBV-infected memory B cells that undergo
plasma cell differentiation are able to switch from a latent to lytic
cycle.[19] We previously reported an association between
persistent B-cell stimulation and EBV, HIV,[43,44] and HCV[45]
replication in HIV-infected patients on ART. The shedding of
EBV in mucosal areas raises the question of the local factors
driving EBV replication in breast milk. During lactation,
mammary glands constitute an effector compartment of the
mucosal associated lymphoid tissue.[46] Breast milk B cells display
a phenotype strikingly different from blood B cells with amucosal
homing profile similar to cells located in gut-associated lymphoid
tissue and a higher percentage of large-sized B cells, plasmablasts,
and plasma cells (CD19, CD20 low, CD27 high, CD138)[47] that
are essential for EBV replication. This suggests that a significant
proportion of B cells infected by EBV can initiate replication in
the lactating mammary gland. In this study if SCM occurs or HIV
was detectable in breast milk then increased EBV shedding was
observed. The immune response induced by SCM and HIV
infection may fuel B cell activation, triggering EBV replication in
latently infected cells. Interestingly, we observed a positive
association between SCM and IL-8, but an inverse association
between IL-8 concentration and the quantity of EBV DNA in
samples with SCM and “possible SCM.” This result suggests that
a robust cytokine response during SCMmay limit EBV shedding.
To distinguish complete EBV from naked DNA DNase I
treatment was used as previously described for EBV in plasma
and saliva.[48,49] The low impact of DNase exposure on EBV
DNA concentration in some breast milk samples suggested that a
significant proportion of EBV DNA is encapsidated in the breast
milk. Our observation is in line with a recent study performed in
breast milk samples of mothers from high-risk malaria region.[26]
However, we have not performed infectivity assay to verify the
virulent potential of breast milk EBV.
This study highlights the interplay between SCM and EBV
replication in breast milk. Although asymptomatic, SCM is
characterized by significant changes in the breast milk environ-6
ment, altering the host-virus interplay. EBV shedding in breast
milk is likely to be regulated by immune factors that control local
EBV reactivation. The results presented here suggest that HIV
replication in breast milk as well as SCM facilitate EBV
replication in the mammary gland.
Further studies will be needed to assess the consequences of
high EBV exposure on children during breastfeeding.Acknowledgments
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